Summit Healthcare Acquisition Corp.
| IPO Proceeds, $M | $200.00M |
|---|---|
| IPO Date | Jun 9, 2021 |
| CEO | Bo Tan |
| Left Lead | BofA Securities |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Healthcare in Asia |
| IPO Geography | Asia |
| Target Company | YS Biopharma |
| Deal Announced | Sep 29, 2022 |
| Deal Size, $M | $849.00M |
| Deal Sector | Healthcare |
| Deal Geography | Global |
| SEC Filings | www.sec.gov |
| Approval Vote | Mar 14, 2023 |
| Amendment Vote | TBD |
| Closing Date | Mar 16, 2023 |
| Price | |
|---|---|
| Volume, 3-month avg. | N/A |
No credit card required
Sign in for more on Summit Healthcare Acquisition Corp.:
- Structure and cap table
- 5 directors & officers
- 16 filings and events
- 2 underwriters
- 5 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Bo Tan | 47 | CEO, Co-CIO & Director |
| Ken Poon | 54 | President, Co-CIO & Director |
| Ian Stone | 70 | Director |
| Thomas Folinsbee | 53 | Director |
| Tao Bai | 56 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
| BofA Securities | BR | 19,500,000 | units |
| Futu Securities | 500,000 | ||
| 20,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.
Filings
| May 3, 2021 | Initial S-1 |
| May 25, 2021 |
Amended S-1
Sign In to view filing content. |
| Jun 9, 2021 |
PR announcing pricing of $200mm IPO
Sign In to view filing content. |
| Jun 10, 2021 | 424B4 IPO Prospectus |
| Jul 27, 2021 |
8-K announcing separate trading of common stock and warrants
Sign In to view filing content. |
| Sep 22, 2021 |
Rumor of negotiations with Mirxes
Sign In to view filing content. |
| Sep 29, 2022 |
8-K announcing business combination with YS Biopharma
Sign In to view filing content. |
| Dec 28, 2022 |
F-4 registration statement containing preliminary proxy for YS Biopharma business combination
Sign In to view filing content. |
| Jan 13, 2023 | F-4/A Amendment #1 to registration statement containing preliminary proxy for YS Biopharma business combination |
| Jan 25, 2023 | F-4/A Amendment #2 to registration statement containing preliminary proxy for YS Biopharma business combination |
| Feb 3, 2023 |
F-4/A Amendment #3 to registration statement containing preliminary proxy for YS Biopharma business combination
Sign In to view filing content. |
| Feb 8, 2023 |
DEFM14A Definitive proxy for YS Biopharma business combination
Sign In to view filing content. |
| Feb 21, 2023 |
8-K announcing adjournment of YS Biopharma approval meeting
Sign In to view filing content. |
| Mar 14, 2023 |
8-K with YS Biopharma meeting results
Sign In to view filing content. |
| Mar 16, 2023 |
CA announcing closing of YS Biopharma business combination
Sign In to view filing content. |
| Mar 16, 2023 |
8-K announcing closing of YS Biopharma business combination
Sign In to view filing content. |